Moderna Stock Hits Day Low of $145.16 Amid Price Pressure

Moderna, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 5.77% on August 26, 2026. The stock reached an intraday low of USD 145.16, reflecting a challenging trading session. In terms of performance metrics, Moderna's one-day performance starkly contrasts with the S&P 500, which saw a minimal change of -0.02%. Over the past week, Moderna's stock has decreased by 14.18%, while the S&P 500 fell by just 0.42%. However, looking at a broader timeframe, Moderna has shown remarkable growth over the past month, with a staggering increase of 176.79%, significantly outpacing the S&P 500's 3.56% gain. Despite its impressive one-year performance of 505.18%, the stock's volatility is evident, particularly when compared to the S&P 500's 18.71% increase over the same period. With a market capitalization of USD 19,573 million, Moderna continues to navigate a complex financial landscape, marked by a return on equity of -32.62% and a price-to-book ratio of 2.26.